MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - March 06, 2012) -
MorphoSys AG /
MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Study Data Expected in Q3 2012
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
successful completion of patient enrollment in its phase 1b/2a clinical
evaluating MOR103, a HuCAL antibody targeting GM-CSF (granulocyte
colony stimulating factor). 96 patients with active rheumatoid arthritis
have been randomized in the double-blind, placebo-controlled study at
clinical centers in Europe to evaluate the safety and preliminary signs
clinical activity of MOR103 when administered intravenously in multiple
Data from the trial will become available in Q3 2012.
"Within the past months, MorphoSys's entire proprietary portfolio has
significantly," commented Dr. Arndt Schottelius, Chief Development Officer
MorphoSys AG. "We currently have four proprietary programs in clinical
all of them targeting novel or better treatment options for severe diseases.
are well on track to expect a whole range of exciting news from our
development portfolio in the years to come. GM-CSF is strongly implicated in
pathogenesis of inflammatory diseases, including rheumatoid arthritis.
generated with an antibody targeting the GM-CSF receptor last year
further clinical validation of the GM-CSF pathway in RA."
In addition to the RA study, MOR103 is currently being evaluated in
additional clinical trials. Patient enrollment in a phase 1b dose-
study in multiple sclerosis began in early 2012. A phase 1 pharmacokinetic
in healthy volunteers to evaluate a subcutaneous formulation of MOR103
recruit the final cohort shortly. Subcutaneous injection represents a
convenient route of administration for patients and the data will help
dosing regimens for future clinical trials for MOR103.
In total, MorphoSys currently has four proprietary clinical programs
including MOR103 in RA and MS, as well as MOR202, a HuCAL antibody
CD38, in multiple myeloma and MOR208, an Fc-enhanced humanized
targeting CD19, in chronic lymphocytic leukemia and other B-cell malignancies.
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare. The
company's AbD Serotec unit uses HuCAL and other antibody technologies to
superior monoclonal antibodies for research and diagnostic applications.
Together with its pharmaceutical partners, MorphoSys has built a
Therapeutic pipeline of more than 70 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For
regular updates about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, Ylanthia®,
RapMAT® and arYla® are registered trademarks of MorphoSys AG.
This communication contains certain forward-looking statements concerning
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking statements
far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE